Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs Clinical research trials and A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs. A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs clinical trial. Subjects frequently obtain the most expert healthcare possible for their A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs



A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
Details: In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.
Eligibility:
Study Type:  Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - CD4 count greater than 50 cells/mm3. - HIV RNA less than 50,000 copies/ml. - No active AIDS (excluding CD4 count less than 200 cells/mm3). - Ability to comply with dosing schedule and protocol evaluations. Prior Medication: Allowed: AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs). Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: - Active AIDS (not excluding CD4 count less than 200). - Malabsorption syndrome affecting drug absorption. - Serious medical condition that would compromise safety of the patient. Concurrent Medication: Excluded: - AZT or NNRTIs. - More than 1 week treatment with any protease inhibitor. - Enrollment in any other investigational drug protocol. Patients with the following prior conditions are excluded: History of clinically relevant pancreatitis or hepatitis within the past 6 months. Required: Antiretroviral therapy with either single or double reverse transcriptase inhibitors.
Total Enrollment: 

Location and Contact Information:

Anderson Clinical Research
Pittsburgh,  Pennsylvania,  15213
United States
 


Additional Information:
Study ID Numbers:  280D;  UNAP 12,NZTA 4005
Study Start Date: 
Record last reviewed: May 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002217

Other Hiv Infections Studies:
1. A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.

2. A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients with Weakened Immune Systems

3. An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients with Progressive HIV Disease

4. Testosterone for HIV-Positive Men with Reduced Serum Testosterone Levels and Abdominal Fat

5. A Study of Trimetrexate Plus Leucovorin in Children with Pneumocystis Carinii Pneumonia

Related Studies:

Other HIV Infections Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials

A Study of Combivir plus Abacavir plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
Modify your Search

  Other HIV Infections Clinical Trials
  Other Pennsylvania Clinical Trials
  Other Pittsburgh Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103